Antibody-drug Conjugates & Bioconjugates
PARTNERING & PIPELINE
Catalent Biologics offers flexible options for our partners to employ SMARTag® technology in their bioconjugate and ADC programs, including broad research licenses, target-specific commercial licenses, co-development / product participation deals, and bundled deals including GPEx® cell line development, antibody manufacturing, and analytical services.
Please click here to inquire about potential SMARTag® collaboration opportunities:
- Licensing an asset from our pipeline (including molecules against both solid and hematopoietic tumors)
- Collaborating with us to develop de novo assets using our SMARTag® platform technology and ADC development expertise
Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology
Triphase Accelerator and Catalent Biologics Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma